Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.

Expert opinion on therapeutic targets - 1 May 2018

Silvestris Nicola, Brunetti Oronzo, Pinto Rosamaria, Petriella Daniela, Argentiero Antonella, Fucci Livia, Tommasi Stefania, Danza Katia, De Summa Simona

Abstract excerpt

OBJECTIVES: Adenosquamous cancer of pancreas (ASCP) is a rare variant of pancreatic adenocarcinoma (PDAC). It is characterized by poor prognosis and lacks of literature data supporting the choice of systemic therapies. The role of immunotherapy for this malignancy is still unknown. In this study, we evaluated any differences between immune-related genes of PDAC and its adenosquamous variant with the aim to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to B-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Adenosquamous

Share to Gene Expression Regulation, Neoplastic

Share to Immunotherapy

Share to Pancreatic Neoplasms

Share to T-Lymphocytes

Source

Identifiers

PMID: 29561217
DOI: 10.1080/14728222.2018.1456530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.PMID 29561217Read ↗

A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.Semantic proximity Read ↗

New therapeutic targets in pancreatic cancer.Semantic proximity Read ↗

Genomic signatures of pancreatic adenosquamous carcinoma (PASC).Semantic proximity Read ↗

Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas.Semantic proximity Read ↗

Adenosquamous carcinoma of the pancreas: a distinct clinicopathologic entity.Semantic proximity Read ↗

Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Metaanalysis of transcriptional subtypesSemantic proximity Read ↗

Identification of Genetic Determinants of Pancreatic Cancer Immune Phenotypes by Integrative Genome-scale AnalysisSemantic proximity Read ↗

Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab.Semantic proximity Read ↗

Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.Semantic proximity Read ↗

Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencingSemantic proximity Read ↗

Genomic characterization and prognosis of pancreatic adenosquamous carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.